文献速递肝病

肝实质细胞中caspase 8失活可对小鼠梗阻性胆汁淤积提供保护

Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
PubMed 文献 · J Hepatol · 2018-08-23

该研究在28例人血清和IV期原发性胆汁性胆管炎患者活检组织中观察肝损伤,并在小鼠中采用肝实质细胞或肝细胞特异性Casp8缺失、Ripk3-/-小鼠及胆总管结扎(BDL)2至28天模型,发现Casp8Δhepa小鼠在BDL后28天坏死灶、血清转氨酶和凋亡减少,伴代偿性增殖和胆管反应减弱、炎症减轻及肝纤维化改善,Ripk3-/-小鼠呈相似表型;泛caspase抑制剂IDN-7314降低CASP8水平但未能预防BDL诱导的胆汁淤积。

要点

  • Casp8Δhepa小鼠在BDL后28天坏死灶、血清转氨酶和凋亡减少,代偿性增殖和胆管反应减弱。
  • Casp8Δhepa小鼠炎症减轻且肝纤维化改善,Ripk3-/-小鼠呈相似表型。
  • IDN-7314降低CASP8水平但未能预防BDL诱导的胆汁淤积,且不依赖肝细胞CASP8。

核心结论

  • 肝实质细胞(特别是胆管细胞)中干预CASP8可能是治疗梗阻性胆汁淤积的有益选择,而广泛泛caspase抑制可能触发不良副作用。

研究设计与样本

  • 研究纳入28例人血清及IV期原发性胆汁性胆管炎患者活检组织,并采用肝实质细胞特异性Casp8缺失(Casp8Δhepa)、肝细胞特异性Casp8缺失(Casp8Δhep)及Ripk3-/-小鼠,行胆总管结扎(BDL)2至28天,以Casp8fl/fl和Ripk3+/+小鼠为对照。
  • 研究使用泛caspase抑制剂IDN-7314,并在原代分离肝细胞中研究细胞死亡机制。

主要发现

  • 原发性胆汁性胆管炎患者肝移植组织中活化caspase 3、CASP8和RIPK3过表达。
  • BDL后28天,Casp8Δhepa小鼠坏死灶、血清转氨酶水平和凋亡减少,代偿性增殖和胆管反应减弱。
  • Casp8Δhepa小鼠上述结果与炎症特征减轻和肝纤维化改善相关,Ripk3-/-小鼠呈相似表型。
  • IDN-7314治疗降低CASP8水平,但未能预防BDL诱导的胆汁淤积,且不依赖肝细胞CASP8。

关键数值与推荐

  • 人血清样本n=28;小鼠BDL观察时间2至28天。

临床怎么用

  • 作者认为,针对肝实质细胞(特别是胆管细胞)中CASP8的特异性药物干预可能成为临床治疗梗阻性胆汁淤积的有效替代方案。
  • 作者认为,广泛泛caspase抑制药物可能触发不良副作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Caspase 8 (CASP8) is the apical initiator caspase in death receptor-mediated apoptosis. Strong evidence for a link between death receptor signaling pathways and cholestasis has recently emerged. Herein, we investigated the role of CASP8-dependent and independent pathways during experimental cholestasis. METHODS: Liver injury was characterized in a cohort of human sera (n = 28) and biopsies from patients with stage IV primary biliary cholangitis. In parallel, mice with either specific deletion of Casp8 in liver parenchymal cells (Casp8Δhepa) or hepatocytes (Casp8Δhep), and mice with constitutive Ripk3 (Ripk3-/-) deletion, were subjected to surgical ligation of the common bile duct (BDL) from 2 to 28 days. Floxed (Casp8fl/fl) and Ripk3+/+ mice were used as controls. Moreover, the pan-caspase inhibitor IDN-7314 was used, and cell death mechanisms were studied in primary isolated hepatocytes. RESULTS: Overexpression of activated caspase 3, CASP8 and RIPK3 was characteristic of liver explants from patients with primary biliary cholangitis. Twenty-eight days after BDL, Casp8Δhepamice showed decreased necrotic foci, serum aminotransferase levels and apoptosis along with diminished compensatory proliferation and ductular reaction. These results correlated with a decreased inflammatory profile and ameliorated liver fibrogenesis. A similar phenotype was observed in Ripk3-/- mice. IDN-7314 treatment decreased CASP8 levels but failed to prevent BDL-induced cholestasis, independently of CASP8 in hepatocytes. CONCLUSION: These findings show that intervention against CASP8 in liver parenchymal cells - specifically in cholangiocytes - might be a beneficial option for treating obstructive cholestasis, while broad pan-caspase inhibition might trigger undesirable side effects. LAY SUMMARY: Loss of caspase 8 - a protein involved in programmed cell death - in liver parenchymal cells protects against experimental cholestasis. Therefore, specific pharmacological intervention against caspase 8 might be a valid alternative for the treatment of obstructive cholestasis in the clinic, whereas broad pan-caspase inhibiting drugs might trigger undesirable side effects.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Cubero FJ, Peng J, Liao L, et al. Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis. J Hepatol. 2018. PMID: 30144553. doi:10.1016/j.jhep.2018.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。